Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of LATUDA® (lurasidone HCl) tablets for your patients

ORDER YOUR SAMPLES NOW

Need support? Ask Sunovion Answers for information about LATUDA® (lurasidone HCl)

 

A dedicated team is available 7 days a week, from 8 AM to 12:00 midnight ET, to answer patient's calls at 1-855-552-8832

LEARN MORE

Most Viewed

Two Ways Your Patients Can Save on LATUDA

Request LATUDA Savings Cards for Your Patients

Order packs of 10 cards to help eligible patients save on their LATUDA prescription copays*

  • Copays as little as $15* a month
  • Patients can save up to $125 on every LATUDA prescription fill for up to 12 monthly prescriptions per calendar year
  • Up to $1,500 total savings possible each year
  • Restrictions apply and copay amounts may vary. See terms and conditions below

Provide Your Patients with a 14-Day Supply of LATUDA at No Cost to Them

Order packs of 10 vouchers to help your patients get started with a 14-day supply of LATUDA at no cost.

  • LATUDA is available by prescription only
  • Valid only for eligible patients over 18 with a valid prescription for LATUDA or Legal Guardians of patients between 13 and 17 years of age
  • No substitutions permitted
  • No purchase necessary
  • ONLY one voucher per person and each voucher is qualified for up to 2 redemptions in a twelve (12) month period
 

You must be logged in to request LATUDA Savings Cards or 14-Day supply vouchers.

Please Log in or Register

Sunovion is Dedicated to Providing Access to LATUDA for Patients

 

SAVINGS CARD TERMS AND CONDITIONS

By using this card, you acknowledge that you currently meet the following eligibility criteria:

  • This offer is valid only for eligible patients 18 years of age or older, or Legal Guardians of patients between 13 and 17 years of age. Patients must have a valid prescription for LATUDA within LATUDA’s approved indications. No substitutions permitted.
  • Patients are not eligible if prescriptions are paid in part or full by any state or federally funded health care program, including but not limited to Medicare, Medicaid, VA, DOD or TRICARE, or where prohibited by law.
  • Activation is required to use this card.
  • This card is valid for up to $125 off each prescription fill of up to a 30-day supply, and further limited to 12 qualifying prescription fills.  This card may not be used with any other offer. Patient/Legal Guardian is responsible for the first $15 of the copay or out-of-pocket cost.  Cash-paying patients will save up to $125 off the cost of their prescription after paying the first $15.
  • This program is not health insurance. The amount of the benefit cannot exceed the patient’s out-of-pocket expenses. If requested or required by the patient’s insurance provider, the patient must report the use of this card.
  • Offer valid only in the United States and Puerto Rico. Void where prohibited by law, taxed or restricted.
  • Sunovion reserves the right to rescind, revoke or amend this offer at any time without notice. This offer is not transferable and may not be sold, purchased or traded, or offered for sale, purchase or trade.

To the Patient: You must present this card to the pharmacist along with your prescription to participate in this program. If you have any questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the LATUDA Savings Card program at 1-855-5LATUDA (1-855-552-8832) anytime between 8AM and 12 midnight EST . When you use this card, you are certifying that you have read the enclosed program rules, regulations, and terms and conditions; you have not submitted and will not submit a claim for reimbursement under any federal, state or other governmental program for this prescription; if you are Medicare eligible, you are not enrolled in an employer-sponsored health plan or prescription drug plan for retirees; and you will otherwise comply with the terms mentioned herein.

To the Pharmacist: When you use this card, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state or other governmental program for this prescription.

  • Submit transaction to McKesson Corporation using BIN # 610524
  • If primary coverage exists, input card information as secondary coverage and transmit using the COB segment of the NCPDP transaction.  Applicable discounts will be displayed in the transaction response.
  • Acceptance of this card and your submission of claims for the program are subject to the LoyaltyScript® program Terms and Conditions posted at www.mckesson.com/mprstnc.
  • Patient is not eligible if prescriptions are paid in part or full by any state or federally funded health care program, including but not limited to Medicare or Medicaid, VA, DOD or TRICARE or where prohibited by law.
  • For questions regarding setup, claim transmission, patient eligibility or other issues, call the LoyaltyScript® Savings Card program at 1-866-355-9293 (8:00AM–8:00PM ET, Monday–Friday).

*Must meet eligibility requirements.  For commercially insured patients, this Savings Card covers out-of-pocket expenses greater than $15 per prescription, with up to a maximum benefit of $125 for a 30-day prescription.

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behavior. LATUDA is not approved for use in pediatric patients with depression.

 

CONTRAINDICATIONS: LATUDA is contraindicated in the following:

Cerebrovascular Adverse Reactions, Including Stroke: In clinical trials, elderly subjects with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex, reported with administration of antipsychotic drugs. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of antipsychotic drugs, including LATUDA, intensive symptomatic treatment, and monitoring.

Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes Atypical antipsychotic drugs have caused metabolic changes including:

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Monitor complete blood count in patients with a pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) or history of drug-induced leukopenia/neutropenia. Discontinue LATUDA at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest at the beginning of treatment and when increasing the dose. Monitor patients vulnerable to hypotension and those with cardiovascular and cerebrovascular disease.

Falls: Antipsychotics may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls causing fractures or other injuries. For patients with disease, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold.

Potential for Cognitive and Motor Impairment: Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Use LATUDA with caution in patients who may experience conditions that increase body temperature (e.g., exercising strenuously, exposure to extreme heat, concomitant medication with anticholinergic activity, or being subject to dehydration).

Dysphagia: Antipsychotics, including LATUDA, have been associated with esophageal dysmotility and aspiration, and should be used with caution in patients at risk for aspiration pneumonia.

Most Commonly Observed Adverse Reactions: Commonly observed adverse reactions (≥5% incidence and at least twice the rate of placebo) for LATUDA:

To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at 877-737-7226 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Indications

LATUDA is indicated for:

Before prescribing LATUDA, please read the full Prescribing Information, including Boxed Warnings.